Role of interferons in demyelinating diseases
IFNβ-1b reduces the frequency of major multiple sclerosis attacks by 50 percent. Serial MRI scanning over the course of the clinical trial that led to approval of the agent revealed a significant lessening both in disease activity and in accumulating burden of disease in IFNβ-1b-treated patients compared to placebo-treated controls.
The mechanism by which IFNβ-1b exerts its beneficial effect in multiple sclerosis is unknown. T suppressor cell function fails during MS attacks and is persistently subnormal in multiple sclerosis patients with progressive disease. IFNβ-1b partially restores suppressor function in multiple sclerosis patients.
IFNβ-1b also inhibits release of lymphotoxin, tumor necrosis factor, and interferon gamma, at least in vitro. All three cytokines are toxic to oligodendrocytes. In contrast, production of transforming growth factor β-1 (TGFβ1) is increased by IFNβ-1b. TGFβ1 is an immunosuppressive cytokine. All of the above listed actions of IFNβ-1b could contribute to its beneficial effect. Perhaps all do.
KeywordsMultiple Sclerosis Multiple Sclerosis Patient Suppressor Function Experimental Allergic Encephalomyelitis Million Unit
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Antel JP, Arnason BGW, Medof ME (1979) Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 5: 338–342PubMedCrossRefGoogle Scholar
Arnason BGW (1993) Interferon beta in multiple sclerosis. Neurology 43: 641–643PubMedGoogle Scholar
Arnason BGW, Antel JP (1978) Suppressor cell function in multiple sclerosis. Ann Immunol (Paris) 129C: 159–170Google Scholar
Arnason BGW, Reder AT (1994) Interferons and multiple sclerosis. Clin Neuropharmacol 17: 495–547CrossRefGoogle Scholar
Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Scand 78:318–323Google Scholar
Chiang J, Gloff CA, Yoshizawa CN, Williams GJ (1993) Pharmacokinetics of recombinant human interferon-bser
in healthy volunteers and its effect on serum neopterin. Pharm Res 10: 567–572PubMedCrossRefGoogle Scholar
Dayal AS, Jensen MA, Lledo A, Arnason BGW (1995) Interferon gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1B. Neurology 45: 2173–2177PubMedGoogle Scholar
IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661Google Scholar
Jacobs L, Cookfair D, Rudick R, et al (1994) Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Ann Neurol 36: 259CrossRefGoogle Scholar
Koh D-R, Fung-Leung W-P, Ho A, Gray D, Acha-Orbea H, Mak T-W (1992) Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/-
mice. Science 256: 1210–1213PubMedCrossRefGoogle Scholar
Lu C-Z, Jensen MA, Arnason BGW (1993) Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol 46: 123–128PubMedCrossRefGoogle Scholar
Noronha A, Toscas A, Jensen MA (1990) Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 27: 207–210PubMedCrossRefGoogle Scholar
Noronha A, Toscas A, Jensen MA (1992) Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor cell functions in multiple sclerosis. Ann Neurol 31: 103–106PubMedCrossRefGoogle Scholar
Noronha A, Toscas A, Jensen MA (1993a) Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol 46: 145–154PubMedCrossRefGoogle Scholar
Noronha A, Jensen M, Toscas A (1993b) TGF-b activity in MS: effect of IFN-b. Neurology 43 [Suppl]: 355Google Scholar
Noronha A, Toscas A, Arnason BGW, Jensen M (1994) IFN-beta augments in vivo suppressor function in MS. Neurology 44 [Suppl]: A212Google Scholar
Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987a) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37: 1097–1102PubMedGoogle Scholar
Panitch HS, Folus JS, Johnson KP (1987b) Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis. Ann Neurol 22: 139Google Scholar
Panitch HS, Bever CT, Katz E, Johnson KP (1991a) Upper respiratory tract infections trigger attacks of multiple sclerosis in patients treated with interferon-β [abstract]. J Neuroimmunol 35 [Suppl 1]: 125CrossRefGoogle Scholar
Panitch HS, Folus JS, Johnson KP (1991b) Activated suppressor cells inhibit synthesis of interferon-g in patients with multiple sclerosis and normal subjects [abstract]. J Neuroimmunol 35 [Suppl 1]: 186CrossRefGoogle Scholar
Paty DW, Li DKB (1993) UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis IL MRI analysis results of a multicenter, double-blind, placebo-controlled trial. Neurology 43: 655–661Google Scholar
Spear GT, Paulnock DM, Jordan RL, Meltzer DM, Merritt JA, Borden EC (1987) Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo β-interferon. Clin Exp Immunol 69: 107–115PubMedGoogle Scholar
Sibley WA, Bamford CR, Clark KI (1985) Clinical viral infections and multiple sclerosis. Lancet 1: 1313–1315PubMedCrossRefGoogle Scholar
© Springer-Verlag/Wien 1997